REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19
نویسندگان
چکیده
منابع مشابه
Therapeutic potential of Paclitaxel against COVID-19
The coronavirus disease-2019(COVID-19) was reported in Wuhan, China, in late December 2019 and soon became the most serious global health challenge due to high rate of human-to-human transmission. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), is a single-stranded RNA virus and belongs to the large Coronaviridae family. Paclitaxel, an antineoplastic drug extracted from the Tax...
متن کامل[Interleukin-17 as a therapeutic target in psoriasis].
Psoriasis is a chronic, immune-mediated inflammatory disease that affects up to 1-3% of the general population. An advanced understanding of the immune-pathogenesis of psoriasis has led to the development of new drugs that refine existing treatments or target novel molecular and immunologic pathways. IL-17 and Th17 cells play an important role in the pathogenesis of several autoimmune and immun...
متن کاملApoptosis as a Potential Target in Therapeutic and Vaccine Interventions against Parasitic Diseases
Apoptosis is a physiological cell death that occurs under normal conditions in major biological processes, including the removal of old, damaged, extra, or harmful cells. It plays an important role in natural evolution, tissue homeostasis, removal of cells damaged or infected by viruses, and removal of immune cells activated against self-antigens. The purpose of this review was to examine the r...
متن کاملResponding to Covid-19 — A Once-in-a-Century Pandemic?
SARS-CoV-2 is a highly transmissible respiratory virus causing COVID-19, a disease that has become pandemic. It is the biggest public health concern of this century. The sudden emergence of the novel SARS-CoV-2 has rapidly evolved into a pandemic that posed a serious threat to global health and economy Throughout the COVID-19 pandemic, solving immediate problems and preventing problems are two ...
متن کاملInterleukin-6 as a therapeutic target.
Human IL6 is a cytokine produced by many cell types that has pleiotropic effects. In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Blocking IL6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory diseases (rheumatoid arthritis) without major toxicity. Interestingly, the in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Infection
سال: 2020
ISSN: 0163-4453
DOI: 10.1016/j.jinf.2020.06.063